AU2003287834A1 - Use of aglycon protopanaxadiol in cancer therapy - Google Patents

Use of aglycon protopanaxadiol in cancer therapy

Info

Publication number
AU2003287834A1
AU2003287834A1 AU2003287834A AU2003287834A AU2003287834A1 AU 2003287834 A1 AU2003287834 A1 AU 2003287834A1 AU 2003287834 A AU2003287834 A AU 2003287834A AU 2003287834 A AU2003287834 A AU 2003287834A AU 2003287834 A1 AU2003287834 A1 AU 2003287834A1
Authority
AU
Australia
Prior art keywords
cancer therapy
aglycon protopanaxadiol
protopanaxadiol
aglycon
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287834A
Inventor
Dong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panagin Pharmaceuticals Inc
Original Assignee
Panagin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panagin Pharmaceuticals Inc filed Critical Panagin Pharmaceuticals Inc
Publication of AU2003287834A1 publication Critical patent/AU2003287834A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003287834A 2002-12-19 2003-12-19 Use of aglycon protopanaxadiol in cancer therapy Abandoned AU2003287834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43444002P 2002-12-19 2002-12-19
US60/434,440 2002-12-19
PCT/CA2003/001955 WO2004056372A1 (en) 2002-12-19 2003-12-19 Use of aglycon protopanaxadiol in cancer therapy

Publications (1)

Publication Number Publication Date
AU2003287834A1 true AU2003287834A1 (en) 2004-07-14

Family

ID=32682046

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287834A Abandoned AU2003287834A1 (en) 2002-12-19 2003-12-19 Use of aglycon protopanaxadiol in cancer therapy

Country Status (2)

Country Link
AU (1) AU2003287834A1 (en)
WO (1) WO2004056372A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034963A1 (en) * 2003-10-15 2005-04-21 Panagin Pharmaceuticals Inc. USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER
CN104208074B (en) * 2013-06-01 2017-10-10 复旦大学 Purposes of the 2 α hydroxyl protopanoxadiols in tumor multi-drug resistance reversal agents are prepared
KR101722547B1 (en) * 2015-05-22 2017-04-04 한국과학기술원 Anti-cancer adjuvant comprising panaxadiols compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131999A (en) * 1982-01-30 1983-08-06 Osaka Chem Lab Antitumor agent
JP3160313B2 (en) * 1991-07-01 2001-04-25 勲 北川 Anticancer drug
JPH08291194A (en) * 1995-04-18 1996-11-05 Happy World:Kk Ginseng sapogenin and its production
US6888014B2 (en) * 2001-07-24 2005-05-03 Panagin Pharmaceuticals Inc. Dammarane sapogenins, their use as anti-cancer agents, and a process for producing same
US20030092638A1 (en) * 2001-09-21 2003-05-15 Dong Huang Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
US20060013897A1 (en) * 2002-06-11 2006-01-19 Dong Huang Compositions for cancer therapy saponins or sapogenins

Also Published As

Publication number Publication date
WO2004056372A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AUPS054702A0 (en) Cancer therapy
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1535610A4 (en) Therapeutic agent for cancer
AU2002352799A1 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
AU2003235470A1 (en) Predictive markers in cancer therapy
EP1587837A3 (en) Prostate cancer diagnosis and treatment
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003219555A1 (en) Depsipeptide for therapy of kidney cancer
EP1594433B8 (en) Cancer therapy sensitizer
EP1594433A3 (en) Cancer therapy sensitizer
AU2003233733A1 (en) Compositions for cancer therapy saponins or sapogenins
AU2001232787A1 (en) Airway alkalinization as therapy for airway diseases
AU2003258662A1 (en) Use of 4-amino-quinazolines as anti cancer agents
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
AU2003222449A1 (en) Medicine for treating cancer
AU2003230849A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003287834A1 (en) Use of aglycon protopanaxadiol in cancer therapy
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2003291896A1 (en) Saponins and sapogenins for use in combination therapy for cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase